# MFSD4A

## Overview
MFSD4A is a gene that encodes the protein major facilitator superfamily domain containing 4A, which is a member of the major facilitator superfamily (MFS) of transporters. This protein is characterized by its 12 transmembrane segments, a structural hallmark of MFS proteins, and is involved in the transport of substrates across cellular membranes (Perland2017Structural). MFSD4A has been implicated in various biological processes, including acting as a tumor suppressor in nasopharyngeal carcinoma (NPC) by facilitating the degradation of the EPH receptor A2 (EPHA2), thereby inhibiting cancer progression pathways (Yang2022MFSD4A). The gene's expression levels and post-translational modifications, such as glycosylation, are critical for its function and have been linked to cancer prognosis and metastasis, highlighting its potential as a therapeutic target (Perland2017Structural; Oh2024Genomic).

## Structure
The MFSD4A protein is a member of the major facilitator superfamily (MFS) and is characterized by a structure that includes 12 transmembrane segments (TMS), a common feature among MFS proteins (Perland2017Structural). The primary structure of MFSD4A consists of amino acid sequences that are predominantly hydrophobic and neutral, suggesting a non-polar substrate, possibly sugars (Perland2017Structural). The secondary structure is predicted to include alpha-helices forming the transmembrane segments, with a long cytoplasmic loop between TMS 6 and 7, which is typical for MFS proteins (Perland2017Structural).

The tertiary structure of MFSD4A is predicted to fold into a cylindrical shape, potentially facilitating molecule transfer through a substrate pore (Perland2017Structural). Homology models constructed using the SWISS-MODEL program confirmed the presence of these 12 TMS, with TMS 1, 4, 7, and 10 being closest to the substrate pore (Perland2017Structural). The protein has been observed to produce two bands at 40 kDa and 56 kDa, corresponding to predicted isoforms, indicating the presence of splice variant isoforms (Perland2017Structural). Post-translational modifications include a predicted glycosylation site (Perland2017Structural).

## Clinical Significance
Alterations in the expression of the MFSD4A gene have been implicated in the progression of nasopharyngeal carcinoma (NPC). The gene acts as a tumor suppressor by promoting the degradation of the EPHA2 protein, which in turn inhibits the PI3K-AKT-ERK1/2 signaling pathway and epithelial-mesenchymal transition (EMT). Reduced expression of MFSD4A, often due to hypermethylation of its promoter region, is associated with increased EPHA2 levels, enhanced tumor progression, and poor prognosis in NPC patients (Yang2022MFSD4A). High expression of MFSD4A correlates with better overall survival, disease-free survival, and distant metastasis-free survival in NPC patients, making it a potential prognostic marker and therapeutic target (Yang2022MFSD4A).

In gastric cancer with bone metastasis, MFSD4A is more highly expressed in patients with bone metastasis compared to those without, suggesting a role in the metastatic process. This expression pattern is associated with the activation of the PI3K/AKT/mTOR pathway, which is crucial in cancer progression (Oh2024Genomic). These findings highlight the clinical significance of MFSD4A in various cancers, particularly in its role in tumor suppression and metastasis regulation.

## Interactions
MFSD4A interacts with several proteins, playing a significant role in the regulation of nasopharyngeal carcinoma (NPC). It has been identified as an anti-oncogene that inhibits the malignant progression of NPC by targeting the EPH receptor A2 (EPHA2) for ubiquitination and degradation. This process is facilitated through the recruitment of RNF149, a ubiquitin E3 ligase. The interaction between MFSD4A, EPHA2, and RNF149 is crucial for the ubiquitination and subsequent degradation of EPHA2, which in turn inhibits the downstream PI3K-AKT-ERK1/2 signaling pathway and epithelial-mesenchymal transition (EMT), both of which are involved in cancer progression (Yang2022MFSD4A).

The study by Yang et al. demonstrated these interactions using co-immunoprecipitation and mass spectrometry analyses, confirming that MFSD4A binds to EPHA2 and RNF149. This binding suggests that MFSD4A promotes the ubiquitination and degradation of EPHA2 via RNF149, thereby exerting its tumor-suppressive effects in NPC (Yang2022MFSD4A). These findings highlight the potential of MFSD4A as a therapeutic target in NPC by modulating its interactions with EPHA2 and RNF149.


## References


[1. (Perland2017Structural) Emelie Perland, Sofie Victoria Hellsten, Nadine Schweizer, Vasiliki Arapi, Fatemah Rezayee, Mona Bushra, and Robert Fredriksson. Structural prediction of two novel human atypical slc transporters, mfsd4a and mfsd9, and their neuroanatomical distribution in mice. PLOS ONE, 12(10):e0186325, October 2017. URL: http://dx.doi.org/10.1371/journal.pone.0186325, doi:10.1371/journal.pone.0186325. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0186325)

[2. (Oh2024Genomic) Sujin Oh, Soo Kyung Nam, Keun-Wook Lee, Hye Seung Lee, Yujun Park, Yoonjin Kwak, Kyu Sang Lee, Ji-Won Kim, Jin Won Kim, Minsu Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, and Hyung Ho Kim. Genomic and transcriptomic characterization of gastric cancer with bone metastasis. Cancer Research and Treatment, 56(1):219â€“237, January 2024. URL: http://dx.doi.org/10.4143/crt.2023.340, doi:10.4143/crt.2023.340. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.4143/crt.2023.340)

[3. (Yang2022MFSD4A) Huiyun Yang, Guanjie Qin, Zan Luo, Xiangyun Kong, Chunqiao Gan, Ruyun Zhang, and Wei Jiang. Mfsd4a inhibits the malignant progression of nasopharyngeal carcinoma by targeting epha2. Cell Death &amp; Disease, April 2022. URL: http://dx.doi.org/10.1038/s41419-022-04793-x, doi:10.1038/s41419-022-04793-x. This article has 7 citations.](https://doi.org/10.1038/s41419-022-04793-x)